IP Library › Granted Patent US 8,545,842
Granted Patent B2
US 8,545,842 · App. 12/823,827 · Granted Oct 1, 2013

Polynucleotides encoding IL-17 receptor A antigen binding proteins

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,545,842
App. No.
12/823,827
Granted
Oct 1, 2013
Kind
B2
Abstract

The present invention relates to IL-17 receptor A (IL-17RA or IL-17R) antigen binding proteins, such as antibodies, and the polynucleotide sequences encoding them, as well as host cells, expression vectors, and methods of making IL-17 receptor A antigen binding proteins.

Claims (38)

1. An isolated monoclonal antibody, wherein said antibody is selected from the group consisting of:

a) an antibody comprising a heavy chain sequence comprising SEQ ID NO:427 and a light chain sequence comprising amino acids 21-234 of SEQ ID NO:429;

b) an antibody or fragment thereof comprising a light chain variable region sequence comprising SEQ ID NO:40 and a heavy chain variable region sequence comprising SEQ ID NO:14; and

c) an antibody or fragment thereof comprising a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, a heavy chain CDR3 comprising SEQ ID NO:148, a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, and a light chain CDR3 comprising SEQ ID NO:226, wherein said antibody, or fragment thereof, specifically binds human IL-17 receptor A of SEQ ID NO:431, and wherein said antibody is recombinantly-produced from a Chinese Hamster Ovary (CHO) cell.

2. The antibody of claim 1 , wherein said antibody is an IgG2 antibody.

3. The antibody of claim 2 , wherein said antibody is a human antibody.

4. The antibody of claim 3 , wherein said antibody is glycosylated.

5. The antibody of claim 1 , wherein said antibody comprises a heavy chain sequence comprising SEQ ID NO:427 and a light chain sequence comprising amino acids 21-234 of SEQ ID NO:429, wherein said antibody specifically binds human IL-17 receptor A of SEQ ID NO:431, and wherein said antibody is recombinantly-produced from a Chinese Hamster Ovary (CHO) cell.

6. The antibody of claim 5 , wherein said antibody is an IgG2 antibody.

7. The antibody of claim 6 , wherein said antibody is a human antibody.

8. The antibody of claim 7 , Wherein said antibody is glycosylated.

9. The antibody or fragment thereof of claim 1 , wherein said antibody comprises a light chain variable region sequence comprising SEQ ID NO:40 and a heavy chain variable region sequence comprising SEQ ID NO:14, wherein said antibody specifically binds human IL-17 receptor A of SEQ ID NO:431, and wherein said antibody is recombinantly-produced from a Chinese Hamster Ovary (CHO) cell.

10. The antibody of claim 9 , wherein said antibody is an IgG2 antibody.

11. The antibody of claim 10 , wherein said antibody is a human antibody.

12. The antibody of claim 11 , wherein said antibody is glycosylated.

13. The antibody or fragment thereof of claim 1 , wherein said antibody comprises a heavy chain CDR1 comprising SEQ NO: 146, a heavy chain CDR2 comprising SEQ ID NO: 147, a heavy chain CDR3 comprising SEQ ID NO:148, a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, and a light chain CDR3 comprising SEQ ID NO:226, wherein said antibody specifically binds human IL-17 receptor A of SEQ ID NO:431, and wherein said antibody is recombinantly-produced from a Chinese Hamster Ovary (CHO) cell.

14. The antibody of claim 13 , wherein said antibody is an IgG2 antibody.

15. The antibody of claim 14 , wherein said antibody is a human antibody.

16. The antibody of claim 15 , wherein said antibody is glycosylated.

17. An Isolated monoclonal antibody, wherein said monoclonal antibody is encoded by a polynucleotide selected from the group consisting of:

a) a heavy chain encoding polynucleotide sequence comprising SEQ ID NO: 426 and a light chain encoding polynucleotide sequence comprising nucleotides 84-741 of SEQ ID NO:428;

b) a heavy chain variable region encoding polynucleotide sequence comprising SEQ ID NO:67 and a light chain variable region encoding polynucleotide sequence comprising SEQ ID NO:93; and

c) as light chain CDR1-encoding polynucleotide comprising SEQ ID NO:384, CDR2-encoding polynucleotide comprising SEQ ID NO:385, CDR3-encoding polynucleotide comprising SEQ ID NO:386 and a heavy chain CDR1-encoding polynucleotide comprising SEQ ID NO:305, CDR2-encoding polynucleotide comprising SEQ ID NO:306, CDR3-encoding polynucleotide comprising SEQ ID NO:307, wherein said antibody or fragment thereof specifically binds human IL-17 receptor A of SEQ ID NO:431, and wherein said antibody is recombinantly-produced from a Chinese Hamster Ovary (CHO) cell.

18. The antibody of claim 17 , wherein said antibody is an IgG2 antibody.

19. The antibody of claim 18 , wherein said antibody is a human antibody.

20. The antibody of claim 19 , wherein said antibody is glycosylated.

21. The antibody of claim 17 , wherein said antibody is encoded by a heavy chain encoding polynucleotide sequence comprising SEQ ID NO: 426 and a light chain encoding polynucleotide sequence comprising nucleotides 84-741 of SEQ ID NO:428, wherein said antibody specifically binds human IL-17 receptor A of SEQ ID NO:431, and wherein said antibody is recombinantly-produced from a Chinese Hamster Ovary (CHO) cell.

22. The antibody of claim 21 , wherein said antibody is an IgG2 antibody.

23. The antibody of claim 22 , wherein said antibody is a human antibody.

24. The antibody of claim 23 , wherein said antibody is glycosylated.

25. The antibody of claim 13 , wherein said antibody is encoded by a heavy chain variable region encoding polynucleotide sequence comprising SEQ ID NO:67 and a light chain variable region encoding polynucleotide sequence comprising SEQ ID NO:93, wherein said antibody specifically binds human IL-17 receptor A of SEQ ID NO:431, and wherein said antibody is recombinantly-produced from a Chinese Hamster Ovary (CHO) cell.

26. The antibody of claim 25 , wherein said antibody is an IgG2 antibody.

27. The antibody of claim 26 , wherein said antibody is a human antibody.

28. The antibody of claim 27 , wherein said antibody is glycosylated.

29. The antibody of claim 17 , wherein said antibody is encoded a light chain CDR1-encoding polynucleotide comprising SEQ ID NO:384, CDR2-encoding polynucleotide comprising SEQ ID NO:385, CDR3-encoding polynucleotide comprising SEQ ID NO:386 and a heavy chain CDR1-encoding polynucleotide comprising SEQ CDR2-encoding polynucleotide comprising SEQ ID NO:306, CDR3-encoding polynucleotide comprising SEQ ID NO:307, wherein said antibody specifically binds human IL-17 receptor A of SEQ ID NO:431, and wherein said antibody is recombinantly-produced from a Chinese Hamster Ovary (CHO) cell.

30. The antibody of claim 29 , wherein said antibody is an IgG2 antibody.

31. The antibody of claim 30 , wherein said antibody is a human antibody.

32. The antibody of claim 31 , wherein said antibody is glycosylated.

Assignments (3)
CHANGE OF NAME Recorded Mar 26, 2020
From: KIRIN-AMGEN, INC.
To: AMGEN K-A, INC.
Reel/Frame 052243/0521 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2020
From: TOCKER, JOEL; PESCHON, JACQUES J.; SMOTHERS, JAMES F.
To: AMGEN INC.
Reel/Frame 052169/0144 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 19, 2013
From: AMGEN INC.
To: KIRIN-AMGEN, INC.
Reel/Frame 030045/0876 →